HF
GANX icon

HRT Financial’s Gain Therapeutics GANX Stock Holding History

HRT Financial’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-55,679
Closed -$179K – 4113
2025
Q4 		$179K Buy
55,679
+35,962
+182% +$96K ﹤0.01% 2660
2025
Q3 		$34K Buy
+19,717
New +$33.3K ﹤0.01% 2640

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

HRT Financial's GANX Position: Q1 2026 in Review

HRT Financial sold out of Gain Therapeutics (GANX) in Q1 2026, closing a stake of 55,679 shares — an estimated $179K sold.

HRT Financial first reported a position in GANX in Q3 2025 and held it in 2 quarters. The position peaked at $179K in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

  • HRT Financial reported no remaining Gain Therapeutics position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 55,679 Gain Therapeutics shares in Q1 2026, an estimated $179K.
  • HRT Financial first reported a position in Gain Therapeutics in Q3 2025 and held it in 2 quarters.
  • HRT Financial's Gain Therapeutics position peaked at $179K in Q4 2025.
  • 42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.